New Genzyme pill will cost patients $310,250 a year - The Boston Globe
Cambridge biotech Genzyme has priced its new pill to treat Gaucher disease at $310,250 a year for the small population of US patients suffering from the rare genetic disorder.
The Wayback Machine - https://web.archive.org/web/20230924024538/https://www.bostonglobe.com/business/2014/09/02/new-genzyme-pill-treat-rare-gaucher-disease-will-cost-patients-year/5thkIb587nKi7zRAb9GgxM/story.html Cambridge biotech Genzyme has priced its new pill to treat Gaucher disease at $310,250 a year for the small population of US patients suffering from the rare genetic disorder. The price — listed as $23,800 for a 28-day supply — is slightly higher than the $300,000 average annual cost of Genzyme's flagship Gaucher treatment Cerezyme, a protein-based enzyme replacement therapy…
saved by
related reading
- Eliglustat - Wikipediaen.wikipedia.org
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher diseasepmc.ncbi.nlm.nih.gov
- GBA Variants and Parkinson Disease: Mechanisms and Treatmentspmc.ncbi.nlm.nih.gov
- Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birthpmc.ncbi.nlm.nih.gov
- FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease | Scientific Americanscientificamerican.com
- Cure all diseasesworksinprogress.news
- Inside the Mafia of Pharma Pricing - BIG by Matt Stollerthebignewsletter.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- How Mark Cuban Is Trying to Disrupt Big Pharma | WSJyoutube.com
- Gene Genies: Inside The Revolutionary Biotech That Can Edit DNA Inside Living Humansforbes.com
- Battle between Vertex, insurers leads to crushing CF drug costsstatnews.com